Hepatopulmonary syndrome differential diagnosis: Difference between revisions
No edit summary |
No edit summary |
||
Line 9: | Line 9: | ||
Mild hypoxemia occurs in 30 percent of patients with chronic liver disease. It may be due to common cardiopulmonary diseases such as congestive heart failure, chronic obstructive pulmonary disease (COPD) or pneumonia. Pulmonary vascular bed malfunction also might be responsible for certain conditions such as Hepatopulmonary syndrome (HPS) and portopulmonary hypertension (PPH). | Mild hypoxemia occurs in 30 percent of patients with chronic liver disease. It may be due to common cardiopulmonary diseases such as congestive heart failure, chronic obstructive pulmonary disease (COPD) or pneumonia. Pulmonary vascular bed malfunction also might be responsible for certain conditions such as Hepatopulmonary syndrome (HPS) and portopulmonary hypertension (PPH). | ||
Hepatopulmonary syndrome (HPS) must be differentiated from portopulmonary hypertension (PPH) and hereditary hemorrhagic telangiectasia (HHT). | Hepatopulmonary syndrome (HPS) must be differentiated from [[portopulmonary hypertension]] (PPH) and [[hereditary hemorrhagic telangiectasia]] (HHT). | ||
Portopulmonary hypertension is often confused with HPS. However, HPS and PPH are not the same disease. Although both are abnormalities of the pulmonary vasculature resulting from liver disease, '''HPS is characterized by vasodilatation''' and hypoxemia whereas '''PPH is characterized by obstruction or narrowing (vasoconstriction)''' of blood vessels with resulting pulmonary arterial hypertension. | Portopulmonary hypertension is often confused with HPS. However, HPS and PPH are not the same disease. Although both are abnormalities of the pulmonary vasculature resulting from liver disease, '''HPS is characterized by vasodilatation''' and hypoxemia whereas '''PPH is characterized by obstruction or narrowing (vasoconstriction)''' of blood vessels with resulting pulmonary arterial hypertension. | ||
Line 29: | Line 29: | ||
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;|Lab Findings | ! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;|Lab Findings | ||
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;|Imaging | ! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;|Imaging | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;| | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;|Histo | ||
pathology | |||
|- | |- | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;|Respiratory symptoms | ! style="background: #4479BA; color: #FFFFFF; text-align: center;|Respiratory symptoms | ||
Line 41: | Line 42: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;|Pulmonary | ! style="background: #4479BA; color: #FFFFFF; text-align: center;|Pulmonary | ||
function test | function test | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;|Chest CT scan/Pulmonary angiography | ! style="background: #4479BA; color: #FFFFFF; text-align: center;|Chest CT scan/ | ||
Pulmonary angiography | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;|99mTc scan | ! style="background: #4479BA; color: #FFFFFF; text-align: center;|99mTc scan | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;|Contrast enhanced echocardiography | ! style="background: #4479BA; color: #FFFFFF; text-align: center;|Contrast enhanced echocardiography | ||
Line 64: | Line 66: | ||
* lung | * lung | ||
* volumes | * volumes | ||
| style="background: #F5F5F5; padding: 5px;" |'''Frequently nonspecific and subtle''' | | style="background: #F5F5F5; padding: 5px;" |'''Frequently nonspecific''' | ||
'''and subtle''' | |||
* Dilated peripheral pulmonary vessels | * Dilated peripheral pulmonary vessels | ||
* Increased [[pulmonary artery]] to [[bronchus]] ratios | * Increased [[pulmonary artery]] to [[bronchus]] | ||
*ratios | |||
* Characteristic findings of intrapulmonary [[vascular]] dilatations | * Characteristic findings of intrapulmonary [[vascular]] dilatations | ||
* Direct arterio-venous communications may be less commonly seen. | * Direct arterio-venous communications may be less commonly seen. | ||
Line 79: | Line 83: | ||
<br /> | <br /> | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" |Plays no | ||
| style="background: #F5F5F5; padding: 5px;" | | |||
role in | |||
diagnosis | |||
| style="background: #F5F5F5; padding: 5px;" |Triad of | |||
* liver disease | |||
* ABG (widened '''alveolar-arterial oxygen gradient''' | |||
* '''Intra-pulmonary vascular dilation''' or arterio-venous communications that result in a '''right-to-left intrapulmonary shunt.''' | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |PPH | | style="background: #DCDCDC; padding: 5px; text-align: center;" |PPH | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" |+ | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" |+ | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" |- | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | - | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" |+ | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" |Hypoxemia | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | |
Revision as of 14:49, 6 September 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Soroush Seifirad, M.D.[2]
Overview
Hepatopulmonary syndrome (HPS) must be differentiated from portopulmonary hypertension (PPH) and hereditary hemorrhagic telangiectasia (HHT).
Differentiating Hepatopulmonary Syndrome from other Diseases
Mild hypoxemia occurs in 30 percent of patients with chronic liver disease. It may be due to common cardiopulmonary diseases such as congestive heart failure, chronic obstructive pulmonary disease (COPD) or pneumonia. Pulmonary vascular bed malfunction also might be responsible for certain conditions such as Hepatopulmonary syndrome (HPS) and portopulmonary hypertension (PPH).
Hepatopulmonary syndrome (HPS) must be differentiated from portopulmonary hypertension (PPH) and hereditary hemorrhagic telangiectasia (HHT).
Portopulmonary hypertension is often confused with HPS. However, HPS and PPH are not the same disease. Although both are abnormalities of the pulmonary vasculature resulting from liver disease, HPS is characterized by vasodilatation and hypoxemia whereas PPH is characterized by obstruction or narrowing (vasoconstriction) of blood vessels with resulting pulmonary arterial hypertension.
Differentiating hepatopulmonary syndrome from other diseases on the basis of pulse oximetry, arterial blood gas (ABG) analysis , contrast enhanced echocardiography; 99mTc scan: lung perfusion scintigraphy with technetium 99mTc labeled macro aggregated albumin, chest CT scan , pulmonary angiography, and pulmonary function test.
On the basis pulse oximetry, arterial blood gas (ABG) analysis, contrast enhanced echocardiography, 99mTc scan (lung perfusion scintigraphy with technetium 99mTc labeled macro aggregated albumin), chest CT scan , pulmonary angiography, and pulmonary function test, hepatopulmonary syndrome (HPS) must be differentiated from portopulmonary hypertension (PPH) and hereditary hemorrhagic telangiectasia (HHT).[1]
Diseases | Clinical manifestations | Para-clinical findings | Gold standard | Additional findings | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Physical examination | |||||||||||||
Lab Findings | Imaging | Histo
pathology | ||||||||||||
Respiratory symptoms | Chronic liver disease symptoms | Platypnea | Orthodeoxia | Chronic liver disease signs | Pulse oximetry | Arterial blood gas (ABG) analysis | Pulmonary
function test |
Chest CT scan/
Pulmonary angiography |
99mTc scan | Contrast enhanced echocardiography | ||||
HSP | + | + (in most of the patients) | + | + | + (in most of the patients) | SaO2<96% |
|
|
Frequently nonspecific
and subtle
|
+ | + (could distinguish between intracardiac and intrapulmonary shunt)
|
Plays no
role in diagnosis |
Triad of
|
|
PPH | + | + | - | - | + | Hypoxemia | ||||||||
HHT | ||||||||||||||
Diseases | Lab 1 | Lab 2 | Lab 3 | Imaging 1 | Imaging 2 | Imaging 3 | Histopathology | Gold standard | Additional findings | |||||
Differential Diagnosis 4 | ||||||||||||||
Differential Diagnosis 5 | ||||||||||||||
Differential Diagnosis 6 |
- Platypnea (increased shortness of breath when the body is in a vertical position) and orthodeoxia (3-10 mmHg reduction in РаО2 in capillary blood during transition from horizontal to vertical position)
- 99mTc scan: lung perfusion scintigraphy with technetium 99mTc labeled macro aggregated albumin
- Chronic liver disease symptoms including, Itching, easy bruising, abdominal fullness, decreased libido, abdominal distension, and fatigue.
- Chronic liver disease signs including spider angioma, red palms, edema, gynecomastia
- Respiratory symptoms including shortness of breath, clubbed fingers, and cyanosis.
- Hepatopulmonary syndrome (HPS) must be differentiated from portopulmonary hypertension (PPH) and hereditary hemorrhagic telangiectasia (HHT).
- Severity of HPS is defined based on PaO2, while below 50 is extremely sever, 50-60 is sever, and more than 60 is defined as moderate to mild.
References
- ↑ Krynytska I, Marushchak M, Mikolenko A, Bob A, Smachylo I, Radetska L et al. (2017) Differential diagnosis of hepatopulmonary syndrome (HPS): Portopulmonary hypertension (PPH) and hereditary hemorrhagic telangiectasia (HHT). Bosn J Basic Med Sci 17 (4):276-285. DOI:10.17305/bjbms.2017.2020 PMID: 28759737